Page last updated: 2024-12-06

rubitecan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID472335
CHEMBL ID77305
CHEBI ID90225
SCHEMBL ID8640
MeSH IDM0213750

Synonyms (69)

Synonym
AC-13389
chebi:90225 ,
CHEMBL77305
9-nitro-20-(s)-camptothecin
9-nitrocamptothecin ,
1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-9-nitro-
9nc
ethyl-hydroxy-nitro-[?]dione
rfs-2000
rubitecan
orathecin
9-nc
st-2617 ,
camptogen
rubitecan (usan/inn)
D04031
91421-42-0
9-nitro-20(s)-camptothecin
1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-9-nitro-
rfs 2000
rfs2000
rubitecan [usan]
1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-10-nitro-, (4s)-
nitrocamptothecin
NCGC00167969-01
N0822
86639-62-5
NCGC00167969-03
NCGC00167969-02
dtxsid7046752 ,
cas-91421-42-0
tox21_112597
dtxcid5026752
unii-h19c446xxb
h19c446xxb ,
rubitecan [usan:inn]
(4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
AKOS015895332
S2288
rubitecan [who-dd]
rubitecan [mart.]
rubitecan [mi]
rubitecan [inn]
SCHEMBL8640
mfcd06656294
9-nitro camptothecin
VHXNKPBCCMUMSW-FQEVSTJZSA-N
(s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
AKOS025149224
Q-100889
9-nitro-(20s)-camptothecin
rubitecanum
AC-25083
AC-33157
(s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
bdbm50248354
BCP06207
Q510113
DB06159
camptothecin, 9-nitro-20(s)
AS-14856
rfs 2000;9-nitrocamptothecin
BRD-K79821389-001-01-9
HY-13744
CS-0007769
EX-A4326
A847954
(19s)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
9-nc, 9-nitro-camptothecin, partaject orathecin, partaject rubitecan, rfs 2000

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" DLPC-only liposome also had no toxic effects."( 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs.
Brayton, C; Gilbert, BE; Knight, V; Seryshev, A, 2002
)
0.31
" Grade 2 toxic effects included nausea/vomiting (9 patients), cough and bronchial irritation (6 patients), fatigue (5 patients), anemia (4 patients), neutropenia (2 patients), anorexia (1 patient), and skin rash around the face mask (1 patient)."( Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies.
Gilbert, BE; Huaringa, A; Knight, V; Loyer, E; Newman, RA; Verschraegen, CF; Walsh, G, 2004
)
0.32
" However, under human physiological conditions, the rapid opening of lactone ring of 9-NC resulting in the formation of inactive and high toxic carboxylate limited its clinical efficacy."( 9-Nitro-20(S)-carbonate-camptothecin (NCP4), a novel prodrug of 9-nitrocamptothecin (9-NC), exhibits potent chemotherapeutic efficacy and improved safety against hepatocarcinoma.
Chen, Y; Pan, J; Qing, C; Sun, Y; Tian, Y; Zhang, Y; Zhou, H; Zhu, Q, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The in vitro pharmacokinetic determination of lactone levels of esters 6a and 7b showed that the biological life span of their lactone forms in human and mouse plasma significantly increased when compared with their mother compounds, camptothecin (3) and 9-nitrocamptothecin (4)."( Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
Cao, Z; Giovanella, B; Harris, N; Kozielski, A; Stehlin, JS; Vardeman, D, 1998
)
0.3
"A phase II trial was instigated to investigate the antitumour activity, the safety and the pharmacokinetic parameters of RFS2000, a recently identified oral topoisomerase I inhibitor, given once daily (1."( Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
Campone, M; Chollet, P; Fety-Deporte, R; Fumoleau, P; Lacombe, D; Lesimple, T; Menten, J; Paoletti, X; Raymond, E; Stupp, R, 2002
)
0.31
" Population pharmacokinetic analysis of both the parent and the metabolite was performed using the nonlinear mixed effect modelling program (NONMEM)."( Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
Beijnen, JH; Mathôt, RA; Rosing, H; Schellens, JH; Schoemaker, NE; Schöffski, P, 2002
)
0.31
" Interindividual variability of the pharmacokinetic parameters ranged from 38% to 49%."( Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
Beijnen, JH; Mathôt, RA; Rosing, H; Schellens, JH; Schoemaker, NE; Schöffski, P, 2002
)
0.31
"An optimal sampling schedule was derived which allowed assessment of the pharmacokinetic parameters of both the parent compound and its metabolite 9-AC after oral administration of rubitecan."( Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
Beijnen, JH; Mathôt, RA; Rosing, H; Schellens, JH; Schoemaker, NE; Schöffski, P, 2002
)
0.31
" Serial plasma and excreta samples were collected and the pharmacokinetic behavior of 9-NC in rats was characterized by specific liquid chromatographic assays."( Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
Du, Y; Li, K; Xu, JH; Zhang, YF; Zhong, DF, 2003
)
0.32
" Pharmacokinetic analysis was performed using non-compartmental analysis."( Pharmacokinetics of lactone, carboxylate and total 9-nitrocamptothecin with different doses and administration routes in rats.
Chen, J; Chu, X; Guo, J; Ping, Q; Song, M, 2006
)
0.33
" Endpoints included pharmacokinetic analyses of 9-NC and etoposide, and treatment-induced modulations of topo I and II expression in peripheral blood mononuclear cells."( Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
Antonia, S; Cantor, A; Fishman, M; Garrett, C; Gump, J; Lush, RM; Munster, PN; Rocha-Lima, C; Simon, GR; Sullivan, DM; Tetteh, L; Williams, C, 2006
)
0.33
" For a pharmacokinetic study, the concentration of 9-NC as the lactone form (9-NC."( 9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.
Dadashzadeh, S; Derakhshandeh, K; Shirazi, FH, 2008
)
0.35
"The 23 patients for a single-dose pharmacokinetic experiment were divided into 3 dosing cohorts."( A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z, 2011
)
0.37
"In the single-dose pharmacokinetic study, the mean ± SD 9-nitrocamptothecin C(max) were 94."( A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z, 2011
)
0.37
" The pharmacokinetic study in rats of these nanoparticles with borneol was carried out."( Effects of borneol on the pharmacokinetics of 9-nitrocamptothecin encapsulated in PLGA nanoparticles with different size via oral administration.
Han, L; Li, R; Qing, J; Qiu, M; Ru, G; Sheng, J; Wang, J, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" On the basis of these studies, our group has begun to evaluate effects of RFS2000 (9-nitro-20(S)-camptothecin) (9-NC) in combination with a series of other antitumor agents."( In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs.
Bernacki, RJ; Brun, Y; Gambacorta, P; Greco, WR; Pera, P, 2000
)
0.31

Bioavailability

Rubitecan (RFS-2000, 9NC, Orathecin) is an orally bioavailable camptothecin analogue. Evidence of preclinical activity in colon cancer cell lines.

ExcerptReferenceRelevance
" A cross-over design was chosen to determine the intrapatient variation of the bioavailability and pharmacokinetics of the anticancer agent depending on the timing of food intake in relation to the oral drug administration."( Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Adank, S; Beijnen, JH; Botma, HJ; Ganser, A; Herr, A; Rosing, H; Schöffski, P; Van den Brande, J; Vermorken, JB; Volk, J; Wanders, J, 2002
)
0.31
" The absolute oral bioavailability of 9-NC was calculated to be 14."( Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
Du, Y; Li, K; Xu, JH; Zhang, YF; Zhong, DF, 2003
)
0.32
" The oral bioavailability of 9-NC was low."( Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
Du, Y; Li, K; Xu, JH; Zhang, YF; Zhong, DF, 2003
)
0.32
" The absolute bioavailability of lactone and total 9-NC were calculated to be 23."( Pharmacokinetics of lactone, carboxylate and total 9-nitrocamptothecin with different doses and administration routes in rats.
Chen, J; Chu, X; Guo, J; Ping, Q; Song, M, 2006
)
0.33
"Rubitecan (RFS-2000, 9NC, Orathecin) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines."( Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W, 2006
)
0.33
"9-Nitrocamptothecin (9-NC) is an orally administered topoisomerase-I inhibitor for the treatment of pancreatic carcinoma, but its oral absorption and bioavailability are poor."( Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
Liu, XY; Lu, JL; Wang, JC; Zhang, Q; Zhang, X; Zhao, H; Zhao, SX; Zhou, SF, 2008
)
0.35
" Though several lipophilic derivatives of CPT have shown interesting oral bioavailability in preclinical and clinical studies, only Topotecan has been approved for this route of administration."( A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
Bermejo, M; Corma, A; Díaz Cabañas, MJ; García-Giménez, JL; Gonzalez-Alvarez, I; Gonzalez-Alvarez, M; Mangas-Sanjuán, V; Rodríguez-Berna, G, 2014
)
0.4
"Our study aimed to develop an amorphous 9-nitrocamptothecin solid dispersion (9-NC-SD) using polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus(®)) for improving its oral bioavailability and antitumor efficacy in vivo."( Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation.
Dong, J; Fu, Y; Gong, T; Lian, X; Lin, Q; Teng, Y; Zhang, J, 2014
)
0.4
"To investigate the effect of the particle size and coadministration of borneol on the pharmacokinetics and bioavailability of entrapped drug in different size poly(lactic-co-glycolic acid) (PLGA) nanoparticles."( Effects of borneol on the pharmacokinetics of 9-nitrocamptothecin encapsulated in PLGA nanoparticles with different size via oral administration.
Han, L; Li, R; Qing, J; Qiu, M; Ru, G; Sheng, J; Wang, J, 2016
)
0.43
"The experiments showed that the encapsulation drug in nanoparticles with size below 200 nm could improve the oral bioavailability of 9-NC."( Effects of borneol on the pharmacokinetics of 9-nitrocamptothecin encapsulated in PLGA nanoparticles with different size via oral administration.
Han, L; Li, R; Qing, J; Qiu, M; Ru, G; Sheng, J; Wang, J, 2016
)
0.43
" The combination of the two strategies provides a potential approach to improve the oral bioavailability of drug."( Effects of borneol on the pharmacokinetics of 9-nitrocamptothecin encapsulated in PLGA nanoparticles with different size via oral administration.
Han, L; Li, R; Qing, J; Qiu, M; Ru, G; Sheng, J; Wang, J, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The present study demonstrates that 9NC selectively inhibits release of HIV-1 from freshly infected monocytoid U937 cells in a dose-response manner."( 9-nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells.
Doniger, J; Hung, CL; Pantazis, P; Sadaie, MR, 1999
)
0.3
" Previous studies demonstrated that drugs delivered to the respiratory tract in liposomal formulation resulted in high pulmonary drug concentration, reduced systemic toxicity, and reduced dosage requirements compared with parenteral and oral administration."( 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
Gilbert, BE; Jia, SF; Kleinerman, ES; Knight, V; Koshkina, NV; Waidrep, C; Worth, LL, 2000
)
0.31
" We also showed that oral dosage with L-9NC had no detectable effect on cancer growth, and thus the benefit from aerosol treatment was due to pulmonary deposition and not the larger fraction of drug deposited in the nose of mice during aerosol treatment which is promptly swallowed."( 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice.
Gilbert, BE; Giovanella, BC; Kleinerman, ES; Knight, V; Koshkina, NV; Waldrep, JC, 2000
)
0.31
" In the second stage, which begins at the first instance of DLT, a two-parameter logistic dose-response model estimates the MTD from the DLT experience of all patients."( Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter, DM, 2002
)
0.31
" Animals were observed for signs of pharmacologic and/or toxicologic effects three times on days of dosing and once daily on nondosing days."( 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs.
Brayton, C; Gilbert, BE; Knight, V; Seryshev, A, 2002
)
0.31
"5 mg/kg on a schedule of two 5-day dosing cycles separated by 2 drug-free days."( Preclinical activity of an i.v. formulation of rubitecan in IDD-P against human solid tumor xenografts.
Chen, SF; Hollister, B; Mishra, A; Sands, H; Stoeckler, JD, 2002
)
0.31
" Rats were dosed with the drug, and the metabolites in the bile were isolated and collected by high-performance liquid chromatography using a gradient elution."( Identification of the metabolites of 9-nitro-20(S)-camptothecin in rats.
Chen, X; Li, K; Li, Y; Zhong, D, 2003
)
0.32
"The purpose is to evaluate the feasibility and safety of aerosol administration of the topoisomerase I inhibitor, 9-nitrocamptothecin, in a liposome formulation, and to recommend a dosage for a Phase II trial for an 8-week daily treatment schedule."( Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies.
Gilbert, BE; Huaringa, A; Knight, V; Loyer, E; Newman, RA; Verschraegen, CF; Walsh, G, 2004
)
0.32
" Dosing 9NC on a mg/m(2) basis does not reduce pharmacokinetic variability."( Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Agarwala, SS; Belani, CP; Egorin, MJ; Fakih, M; Friedland, DM; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Troetschel, M; Trump, DL; Vozniak, M; Wong, MM; Zamboni, WC, 2004
)
0.32
" The Bayesian optimal dose finding suggested a different solution, closest to that of the latter dosing which may be less toxic."( Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.
Gounder, M; Gu, Z; Kudelka, AP; Lee, SJ; Li, JM; Loyer, E; Rubin, EH; Thalasila, A; Verschraegen, CF, 2008
)
0.35
"The 23 patients for a single-dose pharmacokinetic experiment were divided into 3 dosing cohorts."( A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 5.99.1.2 (DNA topoisomerase) inhibitorA topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
pyranoindolizinoquinoline
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
delta-lactoneA lactone having a six-membered lactone ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency63.09570.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency0.12250.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency0.53660.000221.22318,912.5098AID743035; AID743042; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.73880.000214.376460.0339AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.27350.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency1.22210.001019.414170.9645AID743094; AID743140
aryl hydrocarbon receptorHomo sapiens (human)Potency4.21630.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.59560.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency6.30960.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.43940.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency19.95260.000618.41981,122.0200AID1688
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.36000.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.09440.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.80730.005612.367736.1254AID624032; AID624044
Cellular tumor antigen p53Homo sapiens (human)Potency0.40890.002319.595674.0614AID651631; AID720552
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.12420.009610.525035.4813AID1479148
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency4.73080.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency4.73080.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)10.20000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)5.10000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)60.50002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (182)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (61)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1181776Induction of apoptosis in human Caco2 cells assessed as late apoptotic cells at 0.5 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 2.20 +/- 0.77%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID152119Compound was evaluated for antitumor activity against P-338 leukemia in mice, active dose range of the compound; Lowest dose administered, dose range was 2.5-20 mg/kg1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID1181745Induction of apoptosis in human HeLa cells assessed as p53 phosphorylation at Ser15 by Western blotting analysis2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID152098Compound was evaluated for antitumor activity against P-338 leukemia in mice at the dose of 10 mg/kg; T/C=Survival time of treated/control animals*1001986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID1181782Induction of apoptosis in human Caco2 cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID152245Antitumor activity against P-338 leukemia in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID1181777Induction of apoptosis in human Caco2 cells assessed as necrotic cells at 0.05 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.41 +/- 0.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181761Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181784Induction of apoptosis in human MDA-MB-231 cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181780Induction of apoptosis in human Caco2 cells assessed as necrotic cells at 0.5 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.41 +/- 0.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181744Induction of apoptosis in human Caco2 cells assessed as p53 phosphorylation at Ser15 by Western blotting analysis2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1181769Induction of apoptosis in human Caco2 cells assessed as early apoptotic cells at 0.05 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.72 +/- 0.03%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181766Induction of apoptosis in human Caco2 cells assessed as vital cells at 0.5 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 96.67 +/- 1.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181770Induction of apoptosis in human Caco2 cells assessed as early apoptotic cells at 0.5 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.72 +/- 0.03%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181785Induction of apoptosis in human A375 cells assessed as inhibition of DNA synthesis after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID152248Compound was evaluated for antitumor activity against P-338 leukemia in mice. toxic dose range of the compound; Highest dose administered1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID89387In vitro determination of lactone level in human plasma after administration of compound at 4 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181789Induction of apoptosis in human A375 cells assessed as p53 phosphorylation at Ser15 by Western blotting analysis2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181787Induction of apoptosis in human HeLa cells assessed as inhibition of DNA synthesis after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID140633In vitro determination of lactone level in mouse plasma after administration of compound at 4 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181767Induction of apoptosis in human Caco2 cells assessed as vital cells at 0.05 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 96.67 +/- 1.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID140636In vitro determination of lactone level in mouse plasma after administration of compound at 6 hour; Not determined1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181781Induction of apoptosis in human A375 cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID89386In vitro determination of lactone level in human plasma after administration of compound at 2 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181768Induction of apoptosis in human Caco2 cells assessed as vital cells at 0.5 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 96.67 +/- 1.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181762Cytotoxicity against human A375 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID89388In vitro determination of lactone level in human plasma after administration of compound at 6 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181788Induction of apoptosis in human MDA-MB-231 cells assessed as inhibition of DNA synthesis after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181773Induction of apoptosis in human Caco2 cells assessed as late apoptotic cells at 0.05 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 2.20 +/- 0.77%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181764Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181772Induction of apoptosis in human Caco2 cells assessed as early apoptotic cells at 0.5 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.72 +/- 0.03%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181771Induction of apoptosis in human Caco2 cells assessed as early apoptotic cells at 0.05 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.72 +/- 0.03%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181778Induction of apoptosis in human Caco2 cells assessed as necrotic cells at 0.5 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.41 +/- 0.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1181783Induction of apoptosis in human HeLa cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181774Induction of apoptosis in human Caco2 cells assessed as late apoptotic cells at 0.5 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 2.20 +/- 0.77%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181779Induction of apoptosis in human Caco2 cells assessed as necrotic cells at 0.05 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.41 +/- 0.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID140630In vitro determination of lactone level in mouse plasma after administration of compound at 1 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181746Induction of apoptosis in human MDA-MB-231 cells assessed as p53 phosphorylation at Ser15 by Western blotting analysis2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181760Cytotoxicity against human HeLa cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID140631In vitro determination of lactone level in mouse plasma after administration of compound at 2 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181765Induction of apoptosis in human Caco2 cells assessed as vital cells at 0.05 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 96.67 +/- 1.02%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID1181763Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID140629In vitro determination of lactone level in mouse plasma after administration of compound at 0 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID152112Antitumor activity against P-338 leukemia in mice 1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1181786Induction of apoptosis in human Caco2 cells assessed as inhibition of DNA synthesis after 24 hrs by BrdU staining-based ELISA2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID89385In vitro determination of lactone level in human plasma after administration of compound at 1 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID1181775Induction of apoptosis in human Caco2 cells assessed as late apoptotic cells at 0.05 uM after 48 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 2.20 +/- 0.77%)2014European journal of medicinal chemistry, Aug-18, Volume: 83A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
AID89384In vitro determination of lactone level in human plasma after administration of compound at 0 hour1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (144)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.69)18.7374
1990's31 (21.53)18.2507
2000's87 (60.42)29.6817
2010's20 (13.89)24.3611
2020's5 (3.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials34 (22.82%)5.53%
Reviews9 (6.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other106 (71.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (20)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients [NCT00005869]Phase 30 participants Interventional1998-11-30Active, not recruiting
Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma [NCT00005875]Phase 20 participants Interventional1999-01-31Completed
"Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a 5 Days On-2 Days Off Oral Treatment in Glioblastoma Multiforme" [NCT00005826]Phase 217 participants (Actual)Interventional2000-03-31Completed
Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment [NCT00005871]Phase 30 participants Interventional1998-11-30Active, not recruiting
Phase II and Pharmacokinetic Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Colorectal Cancer Who Have Failed Previous 5-FU Based Chemotherapy [NCT00005877]Phase 20 participants Interventional1999-09-30Active, not recruiting
A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma [NCT00005876]Phase 20 participants Interventional2000-04-30Active, not recruiting
"Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a 5 Days On-2 Days Off Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors" [NCT00006026]Phase 221 participants (Actual)Interventional2000-05-31Completed
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) [NCT00250068]Phase 28 participants (Actual)Interventional2003-04-30Completed
Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas [NCT00005874]Phase 20 participants Interventional1999-06-30Completed
A Phase II Evaluation Of 9-Nitro-Camptothecin In The Third-Line Treatment Of Recurrent Ovarian Or Primary Peritoneal Cancer [NCT00006267]Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to Never activated.)
Phase II Study of RFS 2000 in Relapsed NSCLC [NCT00005872]Phase 20 participants Interventional1999-05-31Completed
"Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a 5 Days On - 2 Days Off Oral Treatment in Advanced Small Cell Lung Cancer" [NCT00006082]Phase 238 participants (Actual)Interventional2000-05-31Completed
Phase I Study of Combination Therapy With Oral 9-Nitrocamptothecin and Oral Etoposide [NCT00006047]Phase 144 participants (Actual)Interventional2000-06-30Completed
"Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a 5 Days On-2 Days Off Oral Treatment in Advanced Ovarian Cancer" [NCT00006230]Phase 251 participants (Actual)Interventional2000-05-31Completed
Aerosol Liposomal 9-Nitro-20(S)-Camptothecin (L9-NC) and Temozolomide in Ewing's Sarcoma and Other Solid Tumors With Lung Involvement [NCT00492141]Phase 1/Phase 210 participants (Actual)Interventional2006-06-30Completed
Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S) - Camptothecin (L9NC) [NCT00250120]Phase 20 participants (Actual)Interventional2003-04-30Withdrawn
Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy [NCT00113256]Phase 2/Phase 339 participants (Actual)Interventional2005-02-28Terminated
Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients [NCT00005870]Phase 30 participants Interventional1999-03-31Active, not recruiting
Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Relapsed Metastatic Breast Cancer [NCT00005873]Phase 20 participants Interventional1999-09-30Completed
Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction [NCT00113113]Phase 154 participants (Anticipated)Interventional2001-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]